Biological Drugs

Focusing on needs that cannot be clinically met, we have built an integrated biological medicine platform that covers the whole value chain. We possess a world-class technical platform for long-term and continuous culture of mammalian cells. This has enabled us to carry out large-scale production of bio-pharmaceuticals. We have developed long-acting recombinant proteins, monoclonal antibodies, therapeutic vaccines, and stem cells. 

We hold intellectual property rights for proUK (Recombinant Human Prourokinase for Injection), an independently developed innovative biological medicine. As an efficient and safe new-generation thrombolytic agent and a major innovative state-level biological medicine (Class I), proUK is used for the treatment of ST-segment elevation acute myocardial infarction. Phase III clinical trial of proUK for use in acute ischemic stroke is going on while the phase II clinical trial of proUK for use in acute pulmonary embolism is also progressing.